Eugene

[email protected]

LATEST

GSK To Close Mfg Plant; Announces Staff Reductions
By

By
GlaxoSmithKline (GSK) is closing part of its cephalosporins antibiotics manufacturing plant in Ulverston, England and planning staff reductions of approximately 200 employees. This follows a strategic review from which GSK…

Bayer Plans Staff Reductions at US Plant Producing Hemophilia Therapies
By

By
Bayer is planning staff reductions of approximately 227 employees at its biologics manufacturing plant in Berkeley, California, which recently began production of its newly approved hemophilia A therapy, Jivi (antihemophilic…

Janssen, Arrowhead Launch $3.7-Billion RNAi Partnership
By

By
Janssen Pharmaceuticals, one of the pharmaceutical companies of Johnson & Johnson, has formed a license and collaboration deal with Arrowhead Pharmaceuticals, a Pasadena, California-based biotechnology company, to develop and commercialize…

GSK Signs T-Cell Manufacturing Deal
By

By
GlaxoSmithKline (GSK) has signed a three-year clinical manufacturing agreement with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), an Allendale, New Jersey-based contract development and manufacturing organization. Under the agreement, HCATS will…

Catalent, Brammer Bio, Datwyler, APC Expand; LabVantage Names CEO
By

By
A roundup of the latest expansions and investments from suppliers, contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs), featuring news from Catalent Pharma Solutions, Brammer Bio, APC,…

Novo Nordisk Announces US Staff Reductions
By

By
Novo Nordisk is planning staff reductions of approximately 250 employees in the US as part of a reorganization resulting from an assessment of resource needs against its business priorities. Last…

Merck & Co. Partners in $695-Million Deal for Cancer Immunotherapies
By

By
Merck & Co. and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have partnered to discover, develop, and commercialize immunotherapies for patients with solid tumor cancers in a…

Sanofi Completes $2.2 Billion Divestiture of European Generics Biz to Advent
By

By
Sanofi has completed its previously announced divestment of its European generics business, Zentiva, to Advent International, a Boston-based private-equity firm, for approximately EUR 1.9 billion ($2.2 billion). The transaction was…

Roche To Acquire Immuno-Oncology Company Tusk Therapeutics in $759-Million Deal
By

By
Roche has acquired Tusk Therapeutics, a Stevenage, UK-based pharmaceutical company focused on immuno-oncology, in a deal worth up to EUR 659 million ($759 million) ($80 million upfront and $675 million).…

Merck & Co., Amazon, Accenture Partner for Cloud-Based Research Platform
By

By
Merck & Co. and Accenture, a management consulting company, have partnered with Amazon Web Services (AWS) to launch a cloud-based informatics research platform designed to help organizations in the life-sciences…